Početna stranicaBMYB34 • BVMF
add
Bristol-Myers Squibb Company BDR
Preth. zaklj. cijena
235,50 R$
Dnevni raspon
234,00 R$ - 235,75 R$
Godišnji raspon
229,79 R$ - 360,03 R$
Tržišna kapitalizacija
88,81 mlr. USD
Prosječna količina
8,00
P/E omjer
-
Prinos dividende
-
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Prihod | 12,27 mlr. | 0,56 % |
Operativni troškovi | 4,78 mlr. | −27,91 % |
Neto dohodak | 1,31 mlr. | −22,02 % |
Neto profitabilnost | 10,68 | −22,44 % |
Zarada po dionici | 1,46 | −29,47 % |
EBITDA | 5,12 mlr. | −1,16 % |
Efektivna porezna stopa | 25,96 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 13,60 mlr. | 104,46 % |
Ukupna imovina | 94,68 mlr. | 0,03 % |
Ukupne obveze | 77,19 mlr. | −0,50 % |
Ukupni kapital | 17,49 mlr. | — |
Dionice u optjecaju | 2,04 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | 27,48 | — |
Povrat imovine | 11,04 % | — |
Povrat kapitala | 15,06 % | — |
Tok novca
Neto promjena novca
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 1,31 mlr. | −22,02 % |
Gotovina od poslovanja | 3,92 mlr. | 68,40 % |
Gotovina iz ulaganja | −473,00 mil. | 64,14 % |
Gotovina iz financiranja | −1,84 mlr. | 54,36 % |
Neto promjena novca | 1,74 mlr. | 157,14 % |
Slobodan tok novca | 4,70 mlr. | 80,99 % |
Više
Bristol-Myers Squibb Company is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are Apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.
BMS's primary research and development sites are located in Lawrence, New Jersey, Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey; Redwood City, California; and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts; Braine-l'Alleud, Belgium; Tokyo, Japan; Hyderabad; Bangalore, India and Wirral, United Kingdom. Wikipedia
Glavni izvršni direktor
Osnovano
1887
Web-lokacija
Zaposlenici
34.100
